

# **Specification of a CRM model**

**Ken Cheung**

**Department of Biostatistics, Columbia University**

**(joint work with Shing Lee @ Columbia)**

Dose-finding workshop March 2010  
Reading, UK

# Agenda

- **Motivation**
- Components of a **CRM model**
  - Dose-toxicity function
  - **Initial guesses of DLT rates**
  - **Prior distribution of model parameter**
- **Example:** A bortezomib trial

# Motivation


- The CRM is a model-based dose-finding method
- **Advantage** (versus algorithmic designs): a coherent approach to contingencies via the model, e.g.,

$$1/3 + 0/3 + 1/1 \dots ?$$

- **Assumption:** The model specification is “good”
- **Practical problem:** Specifying a CRM model can be a complex process ... even for statisticians.

# Motivation

- Target DLT = 20%
- MTD = 6
- The CRM model violates consistency conditions under this true state of nature
- Shen and O'Quigley (1996)



# CRM model

Three steps to specify a CRM model:

1. Dose-toxicity function  $F(x, \beta) = P(\text{DLT at dose } x)$
2. Choose a prior distribution  $G(\beta)$  of  $\beta$ .
3. Get the dose labels  $\{d_1, d_2, \dots, d_K\}$  for the  $K$  test doses via *backward substitution*:
  - Let  $p_{i0}$  denote initial guess of DLT rate for dose  $i$ . The dose label  $d_i$  is calculated by solving

$$F\{d_i, E_G(\beta)\} = p_{i0}$$

where  $E_G(\beta)$  is the prior mean of  $\beta$ .

# CRM model

- Thus, the model parameters are

$(F, G, p_{10}, p_{20}, \dots, p_{K0})$

Dose-toxicity function,  
e.g., empiric  $F(x, \beta) = x^\beta$

Initial guesses of DLT rates

Prior distribution, e.g.,  
 $\beta \sim \text{Exp}(1)$

# CRM model: Literature

- Chevret (1993): For  **$G = \text{Exp}(1)$**  and a given set of  **$p_{10}, p_{20}, \dots, p_{K0}$** 
  - Logistic F with  $a_0 = 3$  is superior to empiric
- Lee and Cheung (2009): For **fixed F and G**
  - we can choose  $p_{10}, p_{20}, \dots, p_{K0}$  to match operating characteristics
- Lee and Cheung (2010): For **fixed F and  $p_{10}, p_{20}, \dots, p_{K0}$** 
  - *A least informative prior* is usually adequate

# **Choice of $p_{0k}$ 's**

## **(Lee and Cheung, 2009)**



# Who should choose $p_{0k}$ 's?

- **Ideal** – clinicians choose the initial guesses for all test doses based on their knowledge/experience
- **Reality** – never done; too difficult
- **Goal 1:** Generate the initial guesses  $p_{0k}$ 's with minimal inputs from clinicians by reducing the dimensionality of the specification problem:
  - Reduce the initial guesses (K numbers) into two clinically interpretable parameters.

# How to choose $p_{0k}$ 's?


- To get  $p_{0k}$ 's we need:
  - The prior MTD,  $v$  = **Starting dose**
  - An acceptable range of DLT rate  $\theta \pm \delta$ , where  $\theta$  is the target DLT rate. E.g.,  $0.25 \pm 0.05$

in addition to other CRM parameters:

- Dose-toxicity function  $F$
- Number of test doses  $K$
- Target DLT rate  $\theta$

# How to choose $p_{0k}$ 's?


- The initial guesses of DLT rates can be obtained using the function `getprior` in the R package ``dfcrm'`



```
> p0 <- getprior(0.05,0.25,3,5,model="logistic")  
> round(p0,digits=2)  
[1] 0.09 0.16 0.25 0.36 0.46
```

# Interpretation of $\delta$

- **Theoretical basis of  $p_{0k}$ 's by the function `getprior`:** The CRM converges to the acceptable range  $\theta \pm \delta$  on the probability scale, a.k.a. indifference interval (Cheung and Chappell, 2002)



# How to choose $\delta$ ?

- **Goal 2:** Choose  $\delta$  empirically (if the clinicians don't call it)
  - Asymptotically, a small  $\delta$  has a small bias.
  - With small-moderate sample size, a small  $\delta$  has a large variance of selected MTD.
  - Use simulations to obtain a  $\delta$  that yields competitive operating characteristics over a wide range of scenarios

# Step 1 – Iterate $\delta$

*Specify a CRM model:*

- Logistic function (with fixed intercept):

$$\text{logit} \{ F(\mathbf{x}, \boldsymbol{\beta}) \} = 3 + \exp(\boldsymbol{\beta}) \mathbf{x}$$

- Normal prior  $\boldsymbol{\beta} \sim N(0, 1.34)$
- Target rate  $\theta = 0.25$
- $K = 5$  dose levels
- Prior MTD  $v = 3$  (starting dose)
- **Iterate  $\delta$  from 0.01 to 0.24**

# Step 2 – Simulate





*For each  $\delta$ ,*

Run CRM under the plateau scenarios (calibration set): Record **average** probability of correctly selecting (**PCS**) the MTD

Scene	True $p_1$	True $p_2$	True $p_3$	True $p_4$	True $p_5$
1	<b>0.25</b>	0.40	0.40	0.40	0.40
2	0.14	<b>0.25</b>	0.40	0.40	0.40
3	0.14	0.14	<b>0.25</b>	0.40	0.40
4	0.14	0.14	0.14	<b>0.25</b>	0.40
5	0.14	0.14	0.14	0.14	<b>0.25</b>

# Step 3 – Compare PCS (ave.)

*Choose  $\delta$  with the highest average PCS*





# Choice of $\delta$ : results

Extensive simulations show, for  $N \approx 20$ —40:

- For logistic with  $a_0 = 3$  (Cheung, 2010):
  - For  $\theta = 0.10$ , the optimal  $\delta$  ranges 0.02—0.04
  - For  $\theta = 0.20$ , the optimal  $\delta$  ranges 0.04—0.08
  - For  $\theta = 0.25$ , the optimal  $\delta$  ranges 0.04—0.08
  - For  $\theta = 0.33$ , the optimal  $\delta$  ranges 0.04—0.10
- For empiric, the optimal  $\delta$  is tabulated in Lee and Cheung (2009).

# Choice of prior $G(\beta)$

Dose-finding workshop March 2010  
Reading, UK



# Problem reduction

- Focus on the logistic model with the following parametrization:
  - **Logistic:**  $\text{logit} \{ F(x, \beta) \} = a_0 + \exp(\beta) x$   
and a **normal prior**  $\beta \sim N(0, \sigma^2)$
- Suppose  $p_{01}, \dots, p_{0K}$  are chosen and fixed.
- The CRM model is then completed by specifying the prior standard deviation  $\sigma$ .

# Simulation to get $\sigma$

- 1<sup>st</sup> try: Use the same simulation approach as before:
  1. *Iterate  $\sigma$* : Fix all CRM parameters but  $\sigma$
  2. *Simulate*: Run CRM under the plateau scenarios
  3. *Compare PCS*: Choose  $\sigma$  with the highest average PCS

# Simulation to get $\sigma$ : Results





# Simulation to get $\sigma$ : Problem 1

- Average PCS is quite flat once  $\sigma$  is “large” enough
  - difference less than 3 percentage points
  - The average PCS criterion does not seem sensitive and discriminatory

# Alternative criterion

## *Standard deviation of PCS*



# Simulation to get $\sigma$ : Problem 2

- Range of good  $\sigma$  is dependent on the other design parameters, and is not bounded
  - Good range of  $\sigma$  for logistic: 0.25—0.45
  - Good range of  $\sigma$  for empiric: 0.75—1.50
  - A general exhaustive search is infeasible



# Detour: Least informative prior



- A large  $\sigma$  is **not** vague – on the MTD scale
- Using the above specified logistic model:

$\sigma$	Prior probability $v = \text{dose level}$				
	1	2	3	4	5
0.20	0.09	0.24	0.36	0.23	0.08
<b>0.33</b>	<b>0.21</b>	<b>0.19</b>	<b>0.22</b>	<b>0.19</b>	<b>0.20</b>
1.16	0.41	0.06	0.06	0.06	0.40

# Detour: Least informative prior

- **Definition:** A least informative  $\sigma^{\text{LI}}$  for the normal prior  $G(\beta)$  is a value of  $\sigma$  that gives a prior distribution of  $v$  “closest” to the uniform distribution.
- **Observation:** For the logistic model, simulations show that the least informative prior performs well.

# Detour: Least informative prior



# Simulation to get $\sigma$ : Aided by $\sigma^{\text{LI}}$

- A general search in the neighborhood of least informative prior
  - Evaluate least informative  $\sigma^{\text{LI}}$  (binary search)
  - Iterate  $\sigma$  in the neighborhood of  $\sigma^{\text{LI}}$ , e.g., from  $0.8 \sigma^{\text{LI}}$  to  $1.5 \sigma^{\text{LI}}$ .
  - Choose  $\sigma$  that minimizes standard deviation of PCS over the plateau scenarios (calibration set)

# Example: A bortezomib trial

- Leonard, Furman, Cheung, et al. (2005):  
CHOP-R + escalation dose of bortezomib in  
lymphoma patients

Table 1.1 *Dose schedules of bortezomib used in Leonard et al. (2005) with the sample size (n) and the number of dose-limiting toxicity (z) at each dose.*

Level	Dose and schedule within cycle	n	z
1	0.7 mg/m <sup>2</sup> on day 1 of each cycle	0	0
2	0.7 mg/m <sup>2</sup> on days 1 and 8 of each cycle	0	0
3	0.7 mg/m <sup>2</sup> on days 1 and 4 of each cycle	4	0
4	1.0 mg/m <sup>2</sup> on days 1 and 4 of each cycle	9	1
5	1.3 mg/m <sup>2</sup> on days 1 and 4 of each cycle	7	0

# Example: A bortezomib trial

- **Trial design:**
  - (TITE-)CRM
  - $\theta = 0.25$ ,  $K = 5$ ,  $v = 3$
  - $p_{01} = .05$ ,  $p_{02} = .12$ ,  $p_{03} = .25$ ,  $p_{04} = .40$ ,  $p_{05} = .55$
  - Empiric  $F(x, \beta) = x^{\exp(\beta)}$
  - $\beta \sim N(0, 1.34)$

# Example: A bortezomib trial

- These design parameters were chosen by trial-and-error aided by simulations under the validation scenarios:

Scene	True $p_1$	True $p_2$	True $p_3$	True $p_4$	True $p_5$
1	<b>0.25</b>	0.40	0.45	0.55	0.60
2	0.05	<b>0.25</b>	0.40	0.45	0.55
3	0.05	0.05	<b>0.25</b>	0.45	0.55
4	0.05	0.05	0.08	<b>0.25</b>	0.45
5	0.05	0.05	0.08	0.12	<b>0.25</b>

# Example: A bortezomib trial

	Study model $\sigma = 1.16$	Logistic $\delta = \mathbf{0.07}$ , $\sigma=1.16$	Logistic $\delta=0.07$ , $\sigma = \mathbf{0.35}$
PCS – 1	0.67	0.69	0.62
PCS – 2	<b>0.58</b>	<b>0.57</b>	<b>0.60</b>
PCS – 3	<b>0.68</b>	0.64	<b>0.69</b>
PCS – 4	0.64	0.61	0.66
PCS – 5	0.66	<b>0.70</b>	0.61
PCS (ave)	0.65	0.64	0.64
PCS (std)	0.04	0.05	0.04



# Overall summary

- Simplify the model specification process
  - Get a reasonable  $\delta$ : available from existing tables
  - Get the least informative  $\sigma^{\text{LI}}$ : 5-line code in R
  - (Optional) Iterate in the neighborhood of  $\sigma^{\text{LI}}$
- NOT to improve upon trial-and-error in terms of accuracy, but to provide competitive operating characteristics with an automated model specification; e.g., bortezomib trial

# Resources

- ‘dfcrm’ package in R (<http://www.r-project.org>)
- Lee and Cheung (2009): Model calibration in the CRM. *Clinical Trials* 6:227—238.
- Lee and Cheung (2010):
  - Tabulate  $(\delta, \sigma)$  for a wide range of  $(\theta, K, v, N)$ .
- Cheung (ongoing):
  - Dose-toxicity model F ( $\psi$ -equivalence)
  - Initial designs in two-stage CRM